Farmas USA

Joer, te refieres a ese máximo intra en 0,3983??????? Eso es un un +2800%?????

Un saludo

P.D. ¿Sabeis cómo se hace para marcar un tema y seguirlo?

JEJE a que no te ha llevado mucho tiempo ver lo extraño? Vaya viaje!!

Si te refieres a seguir un hilo yo directamente tengo Farmas USA en favoritos.

Si que parecen buenas y asi te lo demuestra el mercado con el doble del volumen medio en apenas hora y media.
IMUC

liquido 1000 Amrn 7.08 (+7'5%)
Vamos a ver si la bajan de nuevo y recompramos.
Continuo largo de otro paquete.

Pues parece que ha sentado muy bien el comentario del CEO sobre que habra comite para el ANCHOR y que ya se esta preparando la info. Esta vez la mierda del AF no ha surtido efecto.
AMRN

June 7, 2013
ImmunoCellular Therapeutics Announces Recommendation of Data Monitoring Committee to Continue ICT-107 Phase II Trial Following Interim Analysis
Study Completion Anticipated by Year-End 2013

LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced that the Data Monitoring Committee (DMC) has completed a pre-specified interim analysis of the ICT-107 phase II clinical trial in patients with newly diagnosed glioblastoma and recommended that the company continue the trial to completion.

The trial design for the ICT-107 study provides for the interim analysis to be conducted by the independent DMC after 32 events (patient deaths) are reached. ImmunoCellular remains blinded to the actual results and details of the interim analysis and any patient data pertaining to the ongoing trial. No additional interim analyses are planned. The Company anticipates that the phase II trial should be completed by the end of 2013.

"We are pleased with the outcome of the DMC's interim analysis and look forward to completing the ongoing phase II trial of ICT-107," said Andrew Gengos, ImmunoCellular Chief Executive Officer. "We have been pleased with the rate of enrollment and appreciate the diligence of the DMC, our trial site collaborators, and our dedicated clinical team in achieving this important milestone in our Company's progress. The results of this trial will serve as the basis for determining the next clinical and regulatory steps in the development of what we believe is a promising new approach to treating this highly lethal cancer."

The ICT-107 phase II trial is a randomized, placebo-controlled, double-blind study of ICT-107, a 6-antigen dendritic cell vaccine targeting glioblastoma tumor and cancer stem cell antigens, as a potential treatment for patients with newly diagnosed glioblastoma. The phase II trial has been fully enrolled, and a total of 124 patients have been randomized at 25 clinical trial sites in the US. The trial utilizes a one-third, two thirds design: one third of the patients are treated with placebo, which is their own dendritic cells not exposed to antigen, and the treatment arm includes two thirds or about 80 patients who receive the ICT-107 vaccine. The regimen is four induction doses after radiation and chemotherapy, and then maintenance doses until the patient relapses. The primary endpoint of the trial is overall survival (OS). Secondary endpoints include progression-free survival (PFS), OS and PFS at various time intervals, immune response (T cells) and safety.

AMRN

Arriesgado. No ha caído con el homenaje que le hizo ayer el Bastardo y el domingo tendremos datos, que serán mejores que los de la última semana, que eran malillos, entre otras porque la semana tuvo un día festivo, así que lo lógico sería que el lunes subiera.

Edito: no sé por qué anda hoy tan desenfrenada. Es posible que pase algo que no sabemos. Edito 2: 7.18. Qué bestia.

¿Viste el privado que te envié ayer o anteayer?